This document describes the case of a 46-year-old man who presented with vision loss. He was initially diagnosed with viral illness but his vision continued to deteriorate. He was ultimately diagnosed with neuromyelitis optica (NMO) based on clinical features and a positive NMO antibody test. He received treatment including steroids and plasma exchange which improved his vision. His condition was well-controlled with immunosuppression medications.
Electrophysiological assessment of optic neuritis: is there still a roleClare Fraser
Visual evoked potentials were once in the diagnostic criteria for Multiple Sclerosis, but have been left off the most recent criteria. However, there are newer techniques available which are still invaluable in the diagnosis of optic neuritis and its common mimics.
Discussion of clinical approach to typical (demyelnating) and atypical optic neuritis (immune/inflammatory/infectious) optic neuritis with evidence-based review.
Target: Ophthalmologists/Neurologists
Electrophysiological assessment of optic neuritis: is there still a roleClare Fraser
Visual evoked potentials were once in the diagnostic criteria for Multiple Sclerosis, but have been left off the most recent criteria. However, there are newer techniques available which are still invaluable in the diagnosis of optic neuritis and its common mimics.
Discussion of clinical approach to typical (demyelnating) and atypical optic neuritis (immune/inflammatory/infectious) optic neuritis with evidence-based review.
Target: Ophthalmologists/Neurologists
Neuro-ophthalmic Diagnoses You Don't Want To Miss !neurophq8
The presentation will discuss common life-threatening of vision-threatening neuro-ophthalmic emergencies.
Target: Ophthalmologists/Neurologists/Family Physicians/Internists/Emergency Physicians.
Neuro-ophthalmic Diagnoses You Don't Want To Miss !neurophq8
The presentation will discuss common life-threatening of vision-threatening neuro-ophthalmic emergencies.
Target: Ophthalmologists/Neurologists/Family Physicians/Internists/Emergency Physicians.
Diabetic Retinopathy - Long Case Presentation by Dr. Muhammad Zeeshan HameedZeeshan Hameed
About Author:
Dr. Muhammad Zeeshan Hameed MBBS,FCPS (Resident Eye Surgeon)
GMC/DHQ Teachng Hosptal, Gujranwala Pakistan.
About Presentation:
This presentation covers a detailed history and examination of a case of mild NPDR / mild non-proliferative diabetic retinopathy.
A case of Neuromyelitis optica as a presenting manifestation of Systemic Lupu...Apollo Hospitals
Neuromyelitis optica (NMO) is a well characterised, autoimmune, clinicopathological syndrome, which is uncommon and occurs as an isolated entity. Unlike multiple sclerosis, in NMO, the autoimmunity is humorally mediated and the recent availability of Antiaquaporin antibody testing has increased the positive diagnosis of this condition. NMO can also occur in patients with established Systemic Lupus Erythematosis (SLE) who have multiple autoantibodies. The presence of Antiaquaporin antibody is specific for NMO and is seen in patients with SLE who develop inflammatory CNS disease. However, Neuromyelitis optica occurring as a presenting manifestation of SLE is extremely rare and we report one such case.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
2. 46 yo man, Fijian-Indian heritage
6 Feb: family doctor with 2 week history
myalgia
nausea and loss of appetite
blurred vision
Diagnosed as viral illness
Told to increase his thyroxine dose
3. Presents to Eye Emergency Department
blurred vision when reading
vision “fading in and out” in his left eye
denies recent viral illness
denies current systemic symptoms
no headache
no pain on eye movement
4. Past ocular history
myopic
colour blind
Past medical history
Hashimotos thyroiditis
thalassaemia trait
lowVit D
Medications
thyroxine
5. Family history
thalassaemia trait
no vision loss
Social history
works in office, lots of computer work
no cigarettes or alcohol
normal balanced diet
6. RIGHT
6/6
full eye movements
Anterior segment
normal
Dilated fundus exam
normal
LEFT
6/18
50% red desaturation
no RAPD
Anterior segment
normal
Dilated fundus exam
normal
HR 69 reg, BP 100/68, temp 36.8C
7.
8. Resident review
no obvious ocular cause
? bitemporal inferior quadrant field defect
CT scan
normal
Referred for routine clinic follow-up
“left optic neuritis”
9. returns to Eye Emergency
no longer feels safe to drive
myalgia, arthralgia and nausea returned
no neurological symptoms
no headache
no pain on eye movement
10. RIGHT
6/21
full eye movements
Anterior segment
normal
Dilated fundus exam
normal
LEFT
6/120
no red desaturation
no RAPD
Anterior segment
normal
Dilated fundus exam
normal
HR 72 reg, BP 105/70, temp 36.7C
11. Patient didn’t want to wait in emergency for
repeat work-up
very busy at work
Advised not to drive!
Booked for neuro-ophthalmology clinic 2
days later
12. Failed to attend neuro-ophthalmology clinic
patient contacted
really very busy at work
13. Comes back to Eye Emergency
vision is so blurred he can’t work anymore
gradual progression of vision loss
intermittent mild headache
loss of appetite
difficulty sleeping
14. RIGHT
6/120
no RAPD
Anterior segment
normal
Dilated fundus exam
normal
LEFT
Count Fingers at 30cm
no red desaturation
full EOMS, pain in left
Anterior segment
normal
Dilated fundus exam
? slight disc hyperaemia
HR 70 reg, BP 100/70, temp 36.7C
15.
16. Call for a neuro-ophthalmology consult
Admit
Blood tests – inflammatory, infective work-up
Chest X-ray
Lumbar puncture
1g IV methyprednisolone daily
MRI brain/orbits with gadolinium
ordered - outside institution
17. Vision 1/60 right, count fingers left
Fields to confrontation
left central scotoma
right hemi-field red desaturation
Poor pupil response to light OU
0.3 log-unit left RAPD
Cranial nerves normal
Upper and lower limb exam – normal
Anterior and posterior segments - normal
18. full blood count – normal
renal function – normal
liver function – normal
ESR 2, CRP 0.5
chest X-ray – no evidence ofTB or sarcoid
Lumbar puncture - normal opening pressure
and basic constituents
19. “Atypical optic neuritis”
46 year old man
Fijian-Indian
nausea, sleep disturbance
Long lesion suspected
left optic nerve intra-cranially
extending to left optic tract (right hemifield)
neuromyelitis optica until proven otherwise
Ddx: sarcoid
20. anti-AQP4 (NMO) results = 2 weeks
MRI scan can only be done next week
Do you:
continue IVMP?
move rapidly to plasma exchange?
▪ based on clinical diagnosis of NMO
▪ PLEX started within 15-20 days = best outcome
Magana S et al. Beneficial plasma exchange response in central nervous system inflammatory
demyelination. Arch Neurol 2011; 68(7): 870-8
21. 2 days IVMP – no change in vision
Transferred to general hospital
5 days plasma exchange
1g IV methylprednisolone continued 5 days
22.
23.
24.
25.
26.
27.
28. RIGHT
6/60
full EOMs
Anterior segment
normal
Dilated fundus exam
normal
LEFT
6/90
0.3 log-unit RAPD
Anterior segment
normal
Dilated fundus exam
normal
Oral prednisolone 60mg taper, azathoprine increasing to 150mg
29. 1 week after discharge
repeat MRI brain – reduction in lesion size and
intensity
NMO antibody positive
32. 18 months with no relapses
Back at work full-time
Able to return to driving
Final medication:
mycophenolate 500mg BD
thyroxine
Vit D supplement
34. Patient subgroups MS is rare: African, Asian
30s+
Bilateral – simultaneous or sequential loss
Progresses for > 2 weeks
Severe pain > 2 weeks since onset
Require steroids to induce recovery
Cannot apply the findings of the Optic
NeuritisTreatmentTrial
35. Useful after first episode of transverse
myelitis, severe or recurrent ON
Serum autoantibody Aquaporin-4 (AQP4)
One of the major water channel proteins
Sensitivity 50-80% (cell-based higher than ELISA)
Specificity 90-100%
TrebstC et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the
meuromyelitis optica study group (NEMOS). J Neurol 2013; 261: 1-16.
36. Optic neuritis
Transverse myelitis
Within 2 years of each other
Plus 2 of:
Brain MRI non diagnostic for MS
Spinal cord lesion > 3 vertebral segments
Seropositive for NMO-ab (anti-AQP4)
Wingerchuk D et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66(10): 1485-9
37. AQP4-IgG positive longitudinally extensive
transverse myelitis
AQP4-IgG positive recurrent or bilateral optic
neuritis
Wingerchuk D et al.The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6(9):805-15
38. Poor prognosis without treatment
= medical emergency
5 days IV methylprednisolone
Plasmapheresis
immediate improvement 50%
improvement in 6 months in 78%
1mg/kg oral prednisolone – slow taper
Immunosuppression (azathioprine)
Kim S et al. Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum
disorder and effects on circulating anti-aquaporin 4 antibody levels. J Clin Neurol 2013;9(1): 36-42
39. Multiple sclerosis ON Neuromyelitis optica ON
Race Caucasians Asians,Africans
Eye Unilateral Bilateral or sequential
Recovery Spontaneous Poor without steroids
Course of optic neuritis Less severe Profound vision loss
Neurological Varied CNS signs Transverse myelitis
Overall prognosis Good recovery Poor recovery without Rx